PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Hartung, Hans-Peter
TI  - Evolving MS Treatment Strategies
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 26--29
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/26.short
4100  - http://mdc.sagepub.com/content/14/29/26.full
AB  - The assessment of disease activity and burden has evolved from one based on clinical activity to one based on radiologic criteria (eg, number of new/enlarging T2 lesions, number of gadolinium-enhancing [Gd+] lesions, and brain atrophy/black holes). Treatment has moved from slowing disease progression to treatments (eg, natalizumab, fingolimod, interferon beta-1b [IFN-β-1b]) that improve and sustain function.